Drugs / BICX104
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07269873 | Mar → Dec 2026 expected | — | BioCorRx Pharmaceuticals Inc | Recruiting | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-11 | BioCorRx Pharmaceuticals Inc | BioCorRx, Inc. Announces Issuance of U.S. Patent Supporting Its Biodegradable Naltrexone Implant Technology biocorrx.com ↗ |
| 2026-01-14 | BioCorRx Pharmaceuticals Inc | BioCorRx, Inc. Announces Initiation of Clinical Study by Majority-Owned Subsidiary BioCorRx Pharmaceuticals, Inc. Evaluating Long-Acting Naltrexone Implant With or Without Bupropion biocorrx.com ↗ |
| 2024-02-28 | BioCorRx Pharmaceuticals Inc | BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD biocorrx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BICX104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07269873 ↗ |
| Known as | naltrexone | “BICX104 naltrexone implantable pellet” NCT07269873 ↗ |
| Route | Subcutaneous | “subcutaneous implantable pellet” NCT07269873 ↗ |